Navigation Links
Memory Pharmaceuticals Receives Nasdaq Notification
Date:4/4/2008

disease and schizophrenia. For additional information, please visit our website at http://www.memorypharma.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; protecting the intellectual property developed by or licensed to Memory Pharmaceuticals; and Memory Pharmaceuticals' ability to maintain listing on the Nasdaq Global Market. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve t
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
2. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
3. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
4. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
6. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
7. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
8. ASU researchers improve memory devices using nanotech
9. BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
10. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
11. Scientists synthesize memory in yeast cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... 2014 This is a professional ... the Epoxy Hardener industry in Global and ... the industry, including definitions, applications and industry chain ... analysis are provided with a focus on history, ... A comparison between the international and Chinese situation ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
(Date:8/29/2014)... Local veterinarian, Dr. Keith Clement, and his ... to participate in an investigational study of donor stem ... of this study is to determine if a single ... arthritically affected joints can help reduce pain and inflammation ... current investigational study must be older than nine months, ...
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
Breaking Biology Technology:Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... LLC, a clinical-stage drug development company commercializing first-in-class ... completion of a $2.9 million private placement. ... and clinical programs for its lead drug compound, ... David G. Kalergis, Chief Executive Officer of Diffusion ...
... 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China ... CSKI ), a leading,fully integrated pharmaceutical company ... ("PRC"), today announced that the Company,s,Chief Financial Officer, ... meetings at the upcoming Roth 21st Annual OC ...
... Tigris Pharmaceuticals, Inc., a privately held drug development ... Investigational New Drug (IND) application with the U.S. ... novel anticancer compound. GGTI-2418 is a synthetic ... appears to induce apoptosis by downregulating several pivotal ...
Cached Biology Technology:Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 2Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 3China Sky One Medical, Inc. CFO to Present at Roth Conference 2China Sky One Medical, Inc. CFO to Present at Roth Conference 3Tigris Pharmaceuticals Files IND Application for GGTI-2418 2Tigris Pharmaceuticals Files IND Application for GGTI-2418 3
(Date:8/29/2014)... of Texas Medical Branch at Galveston has gone on record ... protect monkeys against a lethal dose of Ebola virus up ... disease is severe. , Thomas Geisbert, professor of microbiology and ... advances in Ebola treatment research. The filoviruses known as Ebola ... pathogens, with fatality rates of up to 90 percent. ...
(Date:8/29/2014)... researchers explored the type and number of connections in ... plays on robustness in a study published in ... found that the assortativity signature contributes to a network,s ... that varying the out-out assortativity of TFN models has ... the other three types of assortativity," said Dov A. ...
(Date:8/29/2014)... This news release is available in German . ... of chemical signals between organisms is considered the oldest ... social interactions between conspecifics, for example, the sexual attraction ... trigger social responses and to coordinate reproductive behavior in ... at the University of the Algarve in Faro, Portugal, ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Assortativity signatures of transcription factor networks contribute to robustness 2Ready for mating at the right time 2Ready for mating at the right time 3
... the observation that a large group of seemingly unconnected ... Now a multi-national research team led by the Melbourne ... has joined the proverbial dots and identified a potential ... paper published today in the prestigious Nature Medicine journal. ...
... (IAA), commonly referred to as auxin, plays a major ... development by affecting the expression of numerous genes that ... in specific plant tissues at specific stages during the ... floral organs to develop in the correct patterns and ...
... them the Dirt Doctors, or Sultans of Soil, they're just ... has a paper in this week's Science Magazine with a ... in the highly complex world beneath our feet. , "Computational ... Soil," by Jason Gans, Murray Wolinsky and John Dunbar, of ...
Cached Biology News:Scientists find microRNAs regulate plant development 2Scientists find microRNAs regulate plant development 3Scientists find microRNAs regulate plant development 4Comparison of Cocaine, Methamphetamine ‘Highs?Finds Differences 2
Schneider's Drosophila - Insect medium...
... and easy operation of a wide range ... The software is fully secure and compliant ... 11 regulations, and compatible with user-created macros ... enables use in high-level research and development ...
... is a proteohormone with a molecular weight of 16 ... ob gene and produced by adipocytes [1,2]. Leptin ... regulation of body weight [1-3]. In the human, ... men and women [4]. A relationship between serum ...
... Components in this kit are prepared ... technology. Biochains Mitochondria Isolation Kit is ... in a fast and easy way. One ... performing 100 isolations (enriching mitochondria from 10 ...
Biology Products: